Last reviewed · How we verify
Durvalumab (Regimen 1)
Durvalumab is a monoclonal antibody that blocks PD-L1, preventing tumor cells from evading immune attack and allowing T cells to recognize and kill cancer cells.
Durvalumab is a monoclonal antibody that blocks PD-L1, preventing tumor cells from evading immune attack and allowing T cells to recognize and kill cancer cells. Used for Unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy, Metastatic or unresectable locally advanced urothelial carcinoma, Biliary tract cancer.
At a glance
| Generic name | Durvalumab (Regimen 1) |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Durvalumab binds to programmed death ligand 1 (PD-L1) on tumor cells and immune cells, blocking the interaction with PD-1 receptors on T cells. This blockade restores anti-tumor immune responses by preventing the inhibitory signal that tumors use to suppress T cell activation and proliferation. By releasing this immune checkpoint brake, durvalumab enables the body's own immune system to mount an effective anti-cancer response.
Approved indications
- Unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy
- Metastatic or unresectable locally advanced urothelial carcinoma
- Biliary tract cancer
Common side effects
- Fatigue
- Pneumonitis
- Diarrhea
- Nausea
- Decreased appetite
- Immune-mediated colitis
- Hepatotoxicity
- Rash
Key clinical trials
- Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery (PHASE2)
- Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens (PHASE1)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and Anxiety (PHASE2)
- Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy (PHASE3)
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Durvalumab (Regimen 1) CI brief — competitive landscape report
- Durvalumab (Regimen 1) updates RSS · CI watch RSS
- AstraZeneca portfolio CI